AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3652464 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 3652464 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 3652464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31813637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg every 4 weeks)
Number of subjects: 303
Study 31813637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg every 2 weeks)
Number of subjects: 303
Study 31813637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 31813637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W and Q2W groups
Number of subjects: 303
Study 31813637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W
Number of subjects: 303
Study 31813637 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 303
Study 28114846 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg progesterone pessaries, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Number of subjects: 700
Study 28114846 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Number of subjects: 700
Study 28114846 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg progesterone pessaries
Number of subjects: 700
Study 28114846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 27653798 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆SVC (superior vena cava diameter)
Number of subjects: 540
Study 27653798 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆VmaxAo (maximal Doppler velocity in left ventricular outflow tract)
Number of subjects: 540
Study 27653798 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆IVC (inferior vena cava diameter)
Number of subjects: 540
Study 27653798 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆PP (pulse pressure variations)
Number of subjects: 540
Study 26643116 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days high dose primaquine
Number of subjects: 0
Study 26643116 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days high dose primaquine
Number of subjects: 0
Study 26643116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26643116 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly primaquine doses for 8 weeks (for G6PD deficient patients)
Number of subjects: 0
Study 23294390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and exercise education, coping skills training, and exercise intervention
Number of subjects: 716
Study 20736505 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for at least 2 weeks
Number of subjects: 87
Study 20736505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for at least 2 weeks
Number of subjects: 87
Study 20736505 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison between omeprazole and rabeprazole groups
Number of subjects: 87
Study 20736505 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment comparison between omeprazole and rabeprazole groups
Number of subjects: 87
Study 18414368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 69
Study 18414368 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 69
Study 15886723 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day racemic fluoxetine
Number of subjects: 13
Study 15886723 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day R-fluoxetine
Number of subjects: 13
Study 15886723 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/day R-fluoxetine
Number of subjects: 13
Study 12818939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (1 mg/kg)
Number of subjects: 66
Study 12818939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 10912700 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin therapy administered transtympanically
Number of subjects: 48
Study 10912700 — intervention group
Group type: COMPARATOR
Intervention: Stable Ménière's disease control group
Number of subjects: 48
Study 10912700 — intervention group
Group type: COMPARATOR
Intervention: Normal-hearing control group
Number of subjects: 48
Study 8860713 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 47
Study 8860713 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering drugs
Number of subjects: 47
Study 1536588 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin and gentamicin
Number of subjects: 81
Study 1536588 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin and aztreonam
Number of subjects: 81
Study 1536588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study 6366725 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 therapy
Number of subjects: 23
Study 6366725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31574237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment in patients aged ≥50 years
Number of subjects: 28546
Study 31574237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives in women <50 years
Number of subjects: 28546
Study 31574237 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous VTE history
Number of subjects: 28546
Study 31574237 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of symptomatic VTE
Number of subjects: 28546
Study 31574237 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rates of VTE
Number of subjects: 28546
Study 30212948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT) intervention for 12 weeks and a follow-up program for 2 weeks
Number of subjects: 86
Study 30212948 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 86
Study 27465076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) therapy
Number of subjects: 29
Study 27465076 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 29
Study 24241327 — intervention group
Group type: EXPERIMENTAL
Intervention: Groin masses (likely hernias)
Number of subjects: 3645
Study 24241327 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for health care
Number of subjects: 3645
Study 24241327 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwent a procedure
Number of subjects: 3645
Study 24241327 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to care
Number of subjects: 3645
Study 24241327 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability assessment
Number of subjects: 3645
Study 22038680 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal balloon training (RBT) with pelvic floor muscle training (PFMT)
Number of subjects: 80
Study 22038680 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) alone
Number of subjects: 80
Study 19852282 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengjing Capsule at a dose of 1.6 g tid for 12 weeks
Number of subjects: 270
Study 19852282 — intervention group
Group type: COMPARATOR
Intervention: Vit E at 50 mg tid for 12 weeks
Number of subjects: 270
Study 17156137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 322
Study 17156137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 16170935 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world warnings presented immediately after reading
Number of subjects: 2
Study 16170935 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world warnings presented after a delay
Number of subjects: 2
Study 16170935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabricated warnings inconsistent with real-world knowledge
Number of subjects: 2
Study 11950380 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 10519449 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasec-40 Gastrocaps (40 mg daily for 5 days)
Number of subjects: 28
Study 10519449 — intervention group
Group type: COMPARATOR
Intervention: Antra 40 (40 mg daily for 5 days)
Number of subjects: 28
Study 7500507 — intervention group
Group type: EXPERIMENTAL
Intervention: Step II Diet and lovastatin (40 mg daily) plus colestipol (30 g daily)
Number of subjects: 146
Study 7500507 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal LDL‐C reduction
Number of subjects: 146
Study 7500507 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial LDL‐C reduction
Number of subjects: 146
Study 7500507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus colestipol if LDL‐C > 90th percentile)
Number of subjects: 146
Study 1789528 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 or 20 mg once a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Number of subjects: 24
Study 1789528 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (600 mg 3 times a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Number of subjects: 24
Study 6948542 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 69
Study 6948542 — intervention group
Group type: EXPERIMENTAL
Intervention: High suspiciousness and high pretreatment symptom scores
Number of subjects: 69
Study 30715997 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 1)
Number of subjects: 65
Study 30715997 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 2)
Number of subjects: 65
Study 30715997 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 65
Study 30715997 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily on a continuous 28-day schedule
Number of subjects: 65
Study 29488430 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 150
Study 29488430 — intervention group
Group type: COMPARATOR
Intervention: Optimized dose of PPI (Control)
Number of subjects: 150
Study 25567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Cesarean Section (PCS)
Number of subjects: 185
Study 25567566 — intervention group
Group type: COMPARATOR
Intervention: Planned Vaginal Delivery (PVD)
Number of subjects: 185
Study 25567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric assessment for twins B born by PVD
Number of subjects: 185
Study 25257046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy using an argon gas-based system (Seednet)
Number of subjects: 25
Study 21805109 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise clamping (3, 6, 12, and 24 hours per day)
Number of subjects: 40
Study 21805109 — intervention group
Group type: COMPARATOR
Intervention: Straightforward clamping
Number of subjects: 40
Study 19602758 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral drotaverine (80 mg) plus mefenamic acid (250 mg)
Number of subjects: 120
Study 19602758 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block with 1% lignocaine
Number of subjects: 120
Study 19602758 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation with diazepam
Number of subjects: 120
Study 19602758 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral drotaverine plus mefenamic acid
Number of subjects: 120
Study 17785361 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological GH therapy
Number of subjects: 30
Study 17785361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15189751 — intervention group
Group type: EXPERIMENTAL
Intervention: TLA 0.5% solution once daily
Number of subjects: 332
Study 15189751 — intervention group
Group type: COMPARATOR
Intervention: TIM 0.5% ophthalmic solution twice daily
Number of subjects: 332
Study 11754786 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Fr Angio-Seal device (group A; n = 75)
Number of subjects: 150
Study 11754786 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (group B; n = 75)
Number of subjects: 150
Study 9517532 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (3-6 MIU three times a week for 6 months)
Number of subjects: 25
Study 9517532 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 25
Study 7905369 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone plus quinidine sulfate (60 mg orally every 8 hours)
Number of subjects: 9
Study 7905369 — intervention group
Group type: COMPARATOR
Intervention: Propafenone plus placebo
Number of subjects: 9
Study 2577015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine sublingual 10-20 mg alone (group I, n = 19)
Number of subjects: 48
Study 2577015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine sublingual 10-20 mg associated with furosemide and clonidine (group II, n = 29)
Number of subjects: 48
Study 2577015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (both groups)
Number of subjects: 48
Study 186089 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine (150 mg i.v.)
Number of subjects: 0
Study 186089 — intervention group
Group type: COMPARATOR
Intervention: Control (no thymoxamine)
Number of subjects: 0
Study 31218354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg b.i.d.
Number of subjects: 10779
Study 31218354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10779
Study 28207549 — intervention group
Group type: EXPERIMENTAL
Intervention: 60° angled stylet
Number of subjects: 140
Study 28207549 — intervention group
Group type: COMPARATOR
Intervention: 90° angled stylet
Number of subjects: 140
Study 25181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan
Number of subjects: 20
Study 25181019 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 20
Study 23085743 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 4 mg/kg once daily for 7-14 days
Number of subjects: 111
Study 23085743 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g twice daily for 7-14 days
Number of subjects: 111
Study 23085743 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 111
Study 23085743 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 111
Study 22185349 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tactile loving-kindness meditation (LKM)
Number of subjects: 10
Study 22185349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile loving-kindness meditation (LKM)
Number of subjects: 10
Study 22185349 — intervention group
Group type: COMPARATOR
Intervention: Baseline (neutral reading)
Number of subjects: 10
Study 22185349 — intervention group
Group type: COMPARATOR
Intervention: Post-Intervention Rest (reading)
Number of subjects: 10
Study 18470565 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent glyceryl trinitrate suppository (n = 21)
Number of subjects: 34
Study 18470565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 34
Study 16482475 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat only (S)
Number of subjects: 28
Study 16482475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of WBV and squat (S+V)
Number of subjects: 28
Study 16482475 — intervention group
Group type: COMPARATOR
Intervention: WBV only (V)
Number of subjects: 28
Study 12414081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessments in English-speaking countries and translated tests in other languages
Number of subjects: 301
Study 12414081 — intervention group
Group type: COMPARATOR
Intervention: Cognitive assessments in English-speaking countries
Number of subjects: 301
Study 12414081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessments in translated languages
Number of subjects: 301
Study 12414081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessments across different countries
Number of subjects: 301
Study 10910008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 18
Study 10910008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9048788 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 (5 mg/kg)
Number of subjects: 31
Study 9048788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (human albumin)
Number of subjects: 31
Study 8103616 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/daily ranitidine
Number of subjects: 54
Study 8103616 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/daily famotidine
Number of subjects: 54
Study 8103616 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/daily nizatidine
Number of subjects: 54
Study 8103616 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/daily omeprazole
Number of subjects: 54
Study 3092894 — intervention group
Group type: EXPERIMENTAL
Intervention: PTBD + hyperalimentation
Number of subjects: 64
Study 3092894 — intervention group
Group type: COMPARATOR
Intervention: PTBD alone
Number of subjects: 64
Study 29521797 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets stored at 4°C for up to 5, 10, or 15 days
Number of subjects: 1500
Study 29521797 — intervention group
Group type: COMPARATOR
Intervention: Platelets stored at 22°C for up to 5 days
Number of subjects: 1500
Study 28490555 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealthcare
Number of subjects: 574
Study 28490555 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 574
Study 26151620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (32 IU)
Number of subjects: 30
Study 26151620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23430442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sox2 overexpression in HCC cells
Number of subjects: 0
Study 23430442 — intervention group
Group type: EXPERIMENTAL
Intervention: High Sox2 expression
Number of subjects: 0
Study 23430442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sox2 expression
Number of subjects: 0
Study 21495216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node sampling and blind biopsies (group A)
Number of subjects: 448
Study 21495216 — intervention group
Group type: COMPARATOR
Intervention: No lymph node sampling (group B)
Number of subjects: 448
Study 21495216 — intervention group
Group type: COMPARATOR
Intervention: No blind biopsies (group C)
Number of subjects: 448
Study 18426137 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 20
Study 18426137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17249435 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% H2O2 + acetone
Number of subjects: 40
Study 17249435 — intervention group
Group type: EXPERIMENTAL
Intervention: H2O2 + ethanol
Number of subjects: 40
Study 17249435 — intervention group
Group type: COMPARATOR
Intervention: acetone
Number of subjects: 40
Study 17249435 — intervention group
Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 40
Study 14994771 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin (oral)
Number of subjects: 20
Study 11129366 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured writing about stressful events
Number of subjects: 105
Study 9488244 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866 10 mg
Number of subjects: 16
Study 9488244 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866 20 mg
Number of subjects: 16
Study 9488244 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866 80 mg
Number of subjects: 16
Study 9488244 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866 (all doses above 5 mg)
Number of subjects: 16
Study 9488244 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866 (2.5 to 10 mg and 5 to 20 mg)
Number of subjects: 16
Study 9488244 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-866
Number of subjects: 16
Study 9488244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8452167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 474
Study 8452167 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 0.5-2 g three times a day or 1-2 g twice a day
Number of subjects: 474
Study 8452167 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled trial with Fleroxacin
Number of subjects: 474
Study 3085738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SV) 800 mg
Number of subjects: 23
Study 3085738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31834177 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week combined training intervention (resistance and aerobic exercise)
Number of subjects: 0
Study 30158160 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral focused ultrasound thalamotomy
Number of subjects: 27
Study 30158160 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 27
Study 27508937 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT) in addition to care as usual (CAU), n = 65
Number of subjects: 131
Study 27508937 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU), n = 66
Number of subjects: 131
Study 24958780 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwood procedure
Number of subjects: 498
Study 24958780 — intervention group
Group type: EXPERIMENTAL
Intervention: Blalock-Taussig shunt
Number of subjects: 498
Study 22632734 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB) exposure three times per week
Number of subjects: 73
Study 22632734 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin D(3) supplementation 1600 IU (40 μg) per day
Number of subjects: 73
Study 22632734 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 20420759 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM) (50 g fat)
Number of subjects: 30
Study 20420759 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate meal (HCM) (5 g fat)
Number of subjects: 30